3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Cyclophosphamide
4
Prednisone
3
Lenalidomide
3
fludarabine phosphate
2
etoposide phosphate
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Stem Cell Transplantation
2
Nivolumab
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Etoposide
2
Doxorubicin
2
Bortezomib
2
Alemtuzumab
2
tazemetostat
1
sargramostim
1
romidepsin
1
poly ICLC
1
plerixafor
1
pegylated granulocyte colony-stimulating factor, human
1
pegfilgrastim
1
pegaspargase
1
liposomal doxorubicin
1
forodesine
1
fludarabine
1
duvelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, T-Cell
×
forodesine
×
Clear all
NCT00742495
2012-10-24
BCX1777-108
Mundipharma Research Limited
Phase 1/2
Terminated
2 enrolled